Last reviewed · How we verify
DMPA 150
At a glance
| Generic name | DMPA 150 |
|---|---|
| Also known as | Depo-Provera® CI (150mg/mL, intramuscular) |
| Sponsor | FHI 360 |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Continuation of Subcutaneous and Intramuscular Depot Medroxyprogesterone Acetate in Post-abortion Patients (PHASE4)
- Kuwa Free! - Live Free! (NA)
- Evaluation of Pharmacokinetic Drug-drug Interactions Between Hormonal Contraceptives and Doravirine-containing ART Among Women Living With HIV in South Africa (PHASE4)
- Comparing the Safety and Efficacy in the Use of Hormonal Therapy on Endometriosis Patients After Conservative Surgery (PHASE3)
- Contraceptive Hormones, Immunity, and Microbiome Evaluation
- Pilot Study of Femring Estrogen Supplementation During Depo-Provera Initiation (NA)
- Pharmacokinetics and Pharmacodynamics of DMPA With HIV PrEP (EARLY_PHASE1)
- Impact of Hormonal Contraception on HIV Acquisition and Transmission Risk (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DMPA 150 CI brief — competitive landscape report
- DMPA 150 updates RSS · CI watch RSS
- FHI 360 portfolio CI